OXiGENE Reports Third Quarter 2009 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News) (Stockholm:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and nine months ended September 30, 2009 and presented an update on recent clinical and corporate progress. Financial Results The Company reported that the consolidated net loss for the third quarter of 2009 was $6.9 million, compared with a consolidated net loss of $7.1 million for the same period in 2008. The consolidated net loss for the quarter ended September 30, 2009 was impacted by the inclusion of the loss attributed to the Company's non-controlling interest in Symphony ViDA, Inc. of $0.5 million. For the nine-month period ended September 30, 2009, the consolidated net loss was $21.5 million, compared to a consolidated net loss of $19.6 million for the comparable period in 2008. The consolidated net loss for the nine-month period ended September 30, 2009 was impacted by the inclusion of the loss attributed to the Company's non-controlling interest in Symphony ViDA, Inc. of $4.2 million. ...
Click here to read the whole Article (external link)

OXIGENE INC Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for OXIGENE INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for OXIGENE INC 9-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not inten...
Click here to read the whole Article (external link)

Q3 2009 OXiGENE, Inc. Earnings Release - Time Not Supplied

Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...
Click here to read the whole Article (external link)

OXiGENE to Present at American Society of Hematology and AACR/NCI/EORTC Meetings

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News) (Stockholm:OXGN - News), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from preclinical studies of its vascular disrupting agent (VDA) drug candidate OXi4503 will be presented at the upcoming meeting of the American Society of Hematology in New Orleans, LA, December 5-8, 2009. Poster # I-53 Poster Title: AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab Presenter: Christopher R. Cogle, MD, Assistant Professor, Medicine, University of Florida Session Name: Acute Myeloid Leukemia - Therapy, excluding Transplantation I Session Date and Time: Saturday, December 5, 2009 5:30 PM - 7:30 PM Location: Ernest N. Morial Convention Center, Hall E As previously announced, the Company will also present interim data from its randomized, controlled, Phase 2 study of ZYBRESTAT(TM) in combination with Avastin(R) (bevacizumab) and chemotherapy in patients with advanced non-small cell lung cancer at a poster session at the upcoming AACR-EORTC-NCI Mo...
Click here to read the whole Article (external link)

OXIGENE INC Files SEC form 10-Q, Quarterly Report

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Our Management's Discussion and Analysis of Financial Condition and Results of Operations as of September 30, 2009 and September 30, 2008 should be read in conjunction with the sections of our audited consolidated financial statements and notes thereto, as well as our "Management's Discussion and Analysis of Financial Condition and Results of Operations" that is included in our Annual Report on Form 10-K for the year ended December 31, 2008, and also with the unaudited financial statements set forth in Part I, Item 1 of this Quarterly Report. Overview We are a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. Our primary focus is the development and commercialization of product candidates referred to as vascular disrupting agents (VDAs) that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival and also are associated with visual impairment in a number of ophthalmological diseases and conditions. To date, more than 400 subjects have been treated to date with ZYBRESTAT in human clinical trials. In light of the significant human experience with ZYBRESTAT to date, and because our VDA product candidates act via a well-characterized therapeutic mechanism, inhibition of blood flow to tumors and to neovascular lesions within the eye, we believe the risk associated with our drug development programs is relatively low as compared with compounds that act via unproven or unknown mechanisms of action. Our most advanced therapeutic product candidate, ZYBRESTATtm (USAN name fosbretabulin, previously known as combretastatin A4 phosphate or CA4P), is currently being evaluated in a Phase II/III pivotal registration study, which we refer to as the FACT Trial, as a potential treatment for anaplastic thyroid cancer (ATC), a highly aggressive and lethal malignancy fo...
Click here to read the whole Article (external link)

OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences

OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-align: le...
Click here to read the whole Article (external link)

OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News) (Stockholm:OXGN - News), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported positive interim safety data from the FALCON (Fosbretabulin in Advanced Lung Oncology) study, a Phase 2, randomized, controlled study of ZYBRESTAT (fosbretabulin) in patients with advanced non-small cell lung cancer (NSCLC). The data from this planned interim safety analysis indicated that the combination of fosbretabulin with carboplatin and paclitaxel plus bevacizumab (Avastin(R)) appeared to be well-tolerated, and that there were no significant overlapping toxicities with bevacizumab. Notably, 5 of the 6 patient deaths during the evaluation period were due to disease progression and occurred in the control arm. The data were presented in a poster by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles, principal investigator for the Phase 2 trial, at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. A further analysis of the efficacy and tolerability of this novel combination is expected to be presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO), scheduled for June 4...
Click here to read the whole Article (external link)

OXIGENE INC Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0930-Sep-08Total Revenue -   -   -  13  Cost of Revenue -   -   -   -  Gross Profit -   -   -  13  Operating ExpensesResearch Development5,978  5,813  4,668  5,004  Selling General and Administrative1,762  2,362  1,965  2,234  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(7,740)(8,175)(6,633)(7,225)Income from Continuing OperationsTotal Other Income/Expenses Net797  209  58  116  Earnings Before Interest And Taxes(6,943)(7,966)(6,575)(7,109)Interest Expense -   -   -   -  Income Before Tax(6,943)(7,966)(6,575)(7,109)Income Tax Expense -   -   -   -  Minority Interest(9,914)3,717   -   -  Net Income From Continuing Ops(16,857)(4,249)(6,575)(7,109)Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   ...
Click here to read the whole Article (external link)

Oxigene drug meets safety goals in study

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

InPlay: OXiGENE reports positive safety data from phase 2 trial of ZYBRESTAT in non-small cell lung cancer

6:26PM Boise Inc. announced that the previously announced secondary offering of 17 mln shares of its common stock has been priced at $4.85 per share (BZ) 5.09 +0.04 :   5:01PM Oncolytics Biotech announces unit offering (ONCY) 3.43 -0.26 : Co announced that it is undertaking an overnight marketed offering of units, each comprised of one common share and a portion of a common share purchase warrant to be effected in each of the Canadian provinces of British Columbia, Alberta, Manitoba and Ontario by way of a prospectus supplement to Oncolytics' base shelf short form prospectus, and in the United States...  ONCY intends to use the net proceeds from the offering to fund its previously announced Phase III combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers, its other clinical development and research and development activities, and for general corporate and working capital purposes. 5:00PM Coldwater Creek announced the resignation of Tim Martin, Senior Vice President and Chief Financial Officer (CWTR) 5.81 -0.27 : Co has appointed John E. Hayes, III, Senior Vice President and General Counsel of Coldwater Creek, to serve as interim Chief Financial Officer, effective November 25, 2009, until a permanent successor is named. 4:55PM Quest Diagnostics announces pricing of tender offer for any and all of certain of its outstanding notes (DGX) 59.07 -0.35 : Co announced the determination of the pricing for its previously announced cash tender offer to purchase any and all of its 5.125% Senior Notes due 2010 and any and all of its 7.50% Senior Notes due 2011. 4:44PM Hampton Roads Bankshares defers dividends on TARP preferred stock (...
Click here to read the whole Article (external link)